Long-term safety of ustekinumab: 5 years of follow-up from the psoriasis clinical development program including patients with psoriatic arthritis

被引：0
|
作者：
Papp, K. [1 ]
Griffiths, C. E. M. [2 ]
Gordon, K. [3 ]
Lebwohl, M. [4 ]
Szapary, P. O. [5 ]
Wasfi, Y. [5 ]
Chan, D. [5 ]
Shen, Y. K. [5 ]
Ho, V. [6 ]
Ghislain, P. D. [7 ]
Strober, B. [8 ]
Reich, K. [9 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Univ Manchester, Manchester Acad Hlth Sci Ctr, Dermatol Ctr, Manchester, Lancs, England
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[4] Mt Sinai Sch Med, New York, NY USA
[5] Janssen Res & Dev LLC, Spring House, PA USA
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
[8] Univ Connecticut, Sch Med, Dept Dermatol, Farmington, CT USA
[9] Dermatologikum Hamburg, Hamburg, Germany
来源：
SWISS MEDICAL WEEKLY | 2014年 / 144卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 14
引用
收藏
页码：5S / 5S
页数：1
相关论文
共 50 条
  • [21] Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
    Langley, R. G.
    Lebwohl, M.
    Krueger, G. G.
    Szapary, P. O.
    Wasfi, Y.
    Chan, D.
    Hsu, M. C.
    You, Y.
    Poulin, Y.
    Korman, N.
    Prinz, J. C.
    Reich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (05) : 1371 - 1383
  • [22] Infection rates in the ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Menter, A.
    Reich, K.
    Szapary, P. O.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB195 - AB195
  • [23] Infection rates in the Ustekinumab psoriasis clinical trial program: Update with up to 4 years of follow-up
    Kimball, A. B.
    Bissonnette, R.
    Leonardi, C.
    Menter, A.
    Szapary, P. O.
    Wasfi, Y.
    Ott, E.
    Hsu, M.
    van de Kerkhof, P.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2012, 53 : 52 - 52
  • [24] Drug Survival, Safety, and Effectiveness of Secukinumab for up to 5 Years in Patients with Psoriasis and Psoriatic Arthritis: A Long-Term Real-Life Experience
    Mastorino, Luca
    Dapavo, Paolo
    Cariti, Caterina
    Susca, Sara
    Siliquini, Niccolo
    Ortoncelli, Michela
    Stroppiana, Elena
    Verrone, Anna
    di Corteranzo, Isotta Giunipero
    Leo, Francesco
    Quaglino, Pietro
    Ribero, Simone
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [25] Clinical manifestations of rheumatoid arthritis, including comorbidities, complications, and long-term follow-up
    Misra, Durga Prasanna
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2025, 39 (01):
  • [26] Risankizumab Long-Term Safety in Patients With Psoriatic Disease: Integrated Interval Analyses From Psoriasis and Psoriatic Arthritis Clinical Trials
    Gordon, Kenneth
    Blauvelt, Andrew
    Coates, Laura C.
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB219 - AB219
  • [27] Infections in the ustekinumab psoriasis clinical trial programme: final report with up to 5 years of follow-up
    Strober, B.
    Ghislain, P. D.
    Lebwohl, M.
    Szapary, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 169 : 38 - 38
  • [28] LONG-TERM SAFETY OF RITUXIMAB IN RHEUMATOID ARTHRITIS: LONG-TERM FOLLOW-UP OF CLINICAL TRIALS AND RETREATMENT POPULATION
    van Vollenhoven, Ronald F.
    Emery, Paul
    Bingham, Clifton O.
    Keystone, Edward C.
    Fleischmann, Roy M.
    Furst, Daniel E.
    Macey, Katherine
    Sweetster, Marianne T.
    Lehane, Patricia B.
    Farmer, Pamela
    Long, Simon G.
    RHEUMATOLOGY, 2010, 49 : I104 - I104
  • [29] Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up
    Fleischmann, Roy
    Genovese, Mark C.
    Lin, Yong
    St John, Gregory
    van der Heijde, Desiree
    Wang, Sheldon
    Jose Gomez-Reino, Juan
    Antonio Maldonado-Cocco, Jose
    Stanislav, Marina
    Kivitz, Alan J.
    Burmester, Gerd R.
    RHEUMATOLOGY, 2020, 59 (02) : 292 - 302
  • [30] Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data
    Gordon, Kenneth
    Blauvelt, Andrew
    Bachelez, Herve
    Coates, Laura
    Kaplan, Blair
    Koetse, Willem
    Drogaris, Leonidas
    Sinvhal, Ranjeeta
    Papp, Kim A.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2791 - 2793
12345